Here's Why Icon PLC (ICLR) Is a Strong Value Stock

Yahoo FinanceJul 10 09:40 ET

Express News | ICON Recognised for Leadership Position in Clinical Research Industry and as Socially Responsible Employer

ReutersJul 10 07:15 ET

Drug Middlemen Pay Higher Prices to Their Own Pharmacies, Says FTC

(July 9): Drug middlemen paid their own mail-order pharmacies as much as 200 times more than the price at rival pharmacies for commonly prescribed cancer drugs, allowing them to bring in at least US$1 billion (RM4.71 billion) in excess revenue and potentially raising the costs to patients, the US Federal Trade Commission (FTC) found in an interim study.

The Edge MarketsJul 10 05:29 ET

Here's How Much You Would Have Made Owning Icon Stock In The Last 15 Years

Icon (NASDAQ:ICLR) has outperformed the market over the past 15 years by 6.54% on an annualized basis producing an average annual return of 19.38%. Currently, Icon has a market capitalization of $26.5

BenzingaJul 8 16:30 ET

Icon Is Maintained at Outperform by Baird

Icon Is Maintained at Outperform by Baird

Dow JonesJul 8 12:08 ET

Icon Price Target Raised to $376.00/Share From $367.00 by Baird

Icon Price Target Raised to $376.00/Share From $367.00 by Baird

Dow JonesJul 8 12:08 ET